Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Timing hormonal therapy in prostate cancer.

Annette E Sessions1, Edward M Messing

  • 1Department of Urology, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA.

The Urologic Clinics of North America
|July 12, 2002
PubMed
Summary

Early androgen ablation therapy offers significant benefits for prostate cancer patients, especially when the disease burden is minimal. Initiating this hormonal treatment sooner may lead to greater advantages in managing prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A risk-adapted approach to reTURBT in high-grade T1 NMIBC.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancer.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

Can urinary tumor DNA be used to assess the risk of recurrence in patients with non-muscle invasive bladder cancer?

Bladder cancer (Amsterdam, Netherlands)·2025
Same author

Excluding PLND in favourable intermediate-risk prostate cancer: a PSMA-PET-directed perspective.

Nature reviews. Urology·2025
Same author

When a 'routine' TURBT is not routine: Lessons from SEER-medicare.

Bladder cancer (Amsterdam, Netherlands)·2025

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Hormonal therapy has a long history in treating prostate cancer.
  • Key treatments include diethylstilboestrol and androgen ablation.

Purpose of the Study:

  • To outline the historical use of hormonal therapy for prostate cancer.
  • To highlight treatment scenarios and disease burdens.
  • To review the benefits of early androgen ablation therapy.

Main Methods:

  • Historical review of hormonal therapies for prostate cancer.
  • Analysis of treatment outcomes based on disease burden.
  • Examination of androgen ablation and anti-androgen therapy efficacy.

Main Results:

  • Diethylstilboestrol therapy has been used historically.

Related Experiment Videos

  • Androgen ablation, alone or with radiation, is a common approach.
  • Early initiation of androgen ablation therapy shows benefits.
  • Maximal benefits of anti-androgen therapy are observed in minimal disease states.

    • Conclusions:

    • Early androgen ablation therapy is beneficial in prostate cancer treatment.
    • The efficacy of anti-androgen therapy is greatest with minimal prostate cancer.
    • Timing of hormonal intervention is crucial for optimal outcomes.